Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clostridium Infections | 3 | 2019 | 49 | 1.530 |
Why?
|
| Surgical Wound Infection | 4 | 2023 | 115 | 1.510 |
Why?
|
| Colon | 3 | 2022 | 146 | 1.450 |
Why?
|
| Laparoscopy | 2 | 2022 | 472 | 1.020 |
Why?
|
| Cross Infection | 3 | 2017 | 161 | 0.990 |
Why?
|
| Hospitals | 4 | 2023 | 393 | 0.920 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2023 | 91 | 0.850 |
Why?
|
| Medicare | 2 | 2023 | 610 | 0.660 |
Why?
|
| Vancomycin | 1 | 2019 | 39 | 0.610 |
Why?
|
| Colectomy | 1 | 2019 | 108 | 0.590 |
Why?
|
| Anti-Bacterial Agents | 3 | 2019 | 787 | 0.550 |
Why?
|
| Glottis | 1 | 2016 | 12 | 0.510 |
Why?
|
| Hypnotics and Sedatives | 1 | 2016 | 66 | 0.500 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2016 | 37 | 0.490 |
Why?
|
| Benzodiazepines | 1 | 2016 | 100 | 0.490 |
Why?
|
| Medication Reconciliation | 1 | 2015 | 13 | 0.490 |
Why?
|
| Home Infusion Therapy | 1 | 2014 | 7 | 0.460 |
Why?
|
| Clinical Protocols | 1 | 2015 | 138 | 0.450 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 42 | 0.450 |
Why?
|
| Pharmacists | 1 | 2015 | 126 | 0.430 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 204 | 0.430 |
Why?
|
| Catheterization, Central Venous | 1 | 2014 | 87 | 0.430 |
Why?
|
| Feces | 1 | 2014 | 112 | 0.430 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 222 | 0.430 |
Why?
|
| Bacteremia | 1 | 2014 | 94 | 0.430 |
Why?
|
| Patient Discharge | 1 | 2015 | 510 | 0.370 |
Why?
|
| Risk Factors | 5 | 2019 | 5327 | 0.340 |
Why?
|
| Retrospective Studies | 5 | 2023 | 6592 | 0.290 |
Why?
|
| Internship and Residency | 1 | 2015 | 800 | 0.280 |
Why?
|
| Humans | 14 | 2023 | 63160 | 0.240 |
Why?
|
| Aged | 5 | 2023 | 14327 | 0.210 |
Why?
|
| Respiration, Artificial | 2 | 2016 | 297 | 0.210 |
Why?
|
| Adult | 5 | 2021 | 16732 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2019 | 2559 | 0.170 |
Why?
|
| United States | 4 | 2023 | 7814 | 0.170 |
Why?
|
| Middle Aged | 5 | 2019 | 17471 | 0.170 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 14 | 0.170 |
Why?
|
| Bronchoscopy | 1 | 2020 | 87 | 0.160 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 5427 | 0.160 |
Why?
|
| Consensus | 1 | 2020 | 230 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2019 | 163 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2019 | 369 | 0.140 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 42 | 0.140 |
Why?
|
| Recurrence | 1 | 2019 | 639 | 0.140 |
Why?
|
| Probiotics | 1 | 2017 | 46 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.130 |
Why?
|
| Male | 5 | 2019 | 29721 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Propofol | 1 | 2016 | 24 | 0.130 |
Why?
|
| Female | 5 | 2019 | 32719 | 0.120 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 39 | 0.120 |
Why?
|
| Logistic Models | 1 | 2019 | 1274 | 0.120 |
Why?
|
| Professional Role | 1 | 2015 | 43 | 0.120 |
Why?
|
| Workflow | 1 | 2015 | 69 | 0.120 |
Why?
|
| Drainage | 1 | 2016 | 154 | 0.120 |
Why?
|
| Hospitals, Teaching | 1 | 2015 | 105 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 672 | 0.120 |
Why?
|
| Pennsylvania | 1 | 2014 | 64 | 0.110 |
Why?
|
| Medication Errors | 1 | 2015 | 109 | 0.110 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2014 | 30 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2014 | 75 | 0.110 |
Why?
|
| Catheters, Indwelling | 1 | 2014 | 69 | 0.110 |
Why?
|
| Chemical Phenomena | 1 | 2014 | 94 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 452 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2016 | 406 | 0.100 |
Why?
|
| Critical Care | 1 | 2016 | 396 | 0.100 |
Why?
|
| Rats | 1 | 2016 | 1980 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 935 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 733 | 0.090 |
Why?
|
| Cephalosporins | 1 | 2012 | 18 | 0.090 |
Why?
|
| Length of Stay | 1 | 2015 | 808 | 0.090 |
Why?
|
| Hemofiltration | 1 | 2012 | 18 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1121 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2015 | 430 | 0.090 |
Why?
|
| Hospitalization | 1 | 2017 | 1356 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1542 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2187 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2014 | 3267 | 0.070 |
Why?
|
| Monkeypox virus | 1 | 2022 | 8 | 0.050 |
Why?
|
| Contact Tracing | 1 | 2022 | 17 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 115 | 0.050 |
Why?
|
| Animals | 1 | 2016 | 20647 | 0.040 |
Why?
|
| Massachusetts | 1 | 2022 | 2074 | 0.030 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2012 | 5 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2012 | 47 | 0.020 |
Why?
|
| Half-Life | 1 | 2012 | 80 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2012 | 228 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2012 | 108 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2012 | 203 | 0.020 |
Why?
|
| Shock, Cardiogenic | 1 | 2012 | 102 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 205 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 4669 | 0.010 |
Why?
|